Correlation between circulating fibrocytes, and activity and progression of interstitial lung diseases

Abstract

The results from this study provide further evidence for the role of circulating fibrocytes in fibrotic lung diseases.

Evaluation of chemokines CXCL8 and CCL2, serotonin, and vascular endothelial growth factor serum concentrations in healthy dogs from seven breeds with variable predisposition for canine idiopathic pulmonary fibrosis

“…Effects of age and gender on serum CCL2 and CXCL8 concentrations were not significant. In humans, both CXCL8 and CCL2 concentrations were found to be increased in blood (Ziegenhagen et al, 1998a;Suga et al, 1999;Fujiwara et al, 2012) and bronchoalveolar lavage fluid (BALF) (Capelli et al, 2005;Antoniou et al, 2006;Baran et al, 2007) of IPF patients compared with healthy volunteers and correlated with lung function (Capelli et al, 2005;Emad and Emad, 2007;Martina et al, 2009;Vasakova et al, 2009), disease progression (Ziegenhagen et al, 1998b;Totani et al, 2002), and outcome (Shinoda et al, 2009;Richards et al, 2012). Furthermore, several studies suggested an involvement of the chemokine CCL2 in the pathogenesis of IPF, notably through its action on resident pulmonary fibroblast and circulating fibrocytes, promoting the generation of abundant extracellular matrix in the lungs (Gharaee-Kermani et al, 1996;Phillips et al, 2004;Moore et al, 2005;Inomata et al, 2014).…”

Fibrocytes in pulmonary fibrosis: a brief synopsis

“…These have been extensively reviewed by PILLING et al [19]. However, there is sufficient evidence that these cells can be reliably identified in the circulation by markers for CD45 and Col-1 [20][21][22][23].…”

“…Work by our group [21], STRIETER et al [29], LAPAR et al [23], and FUJIWARA et al [22] has shown that circulating fibrocytes may have the ability to predict the progression of lung fibrosis. In our study, the survival of IPF patients with circulating fibrocytes .5% of total blood leukocytes was 7.5 months compared with 27 months for patients with ,5% fibrocytes [21].…”

Role of CXCL12/CXCR4-Mediated Circulating Fibrocytes in Pulmonary Fibrosis

“…Fujiwara et al further confirmed a correlation between increased numbers of circulating fibrocytes and activity and progression of interstitial lung diseases (ILD). The number of circulating fibrocytes was significantly and inversely correlated with measurable clinical lung functions parameters including vital capacity (VC) and diffusing capacity of the lung for carbon monoxide/alveolar ventilation (DLco/VA), and positively correlated with serum levels of sialylated carbohydrate antigen (KL-6, an inflammatory biomarker of disease activity) 70 . In addition, there are also positive correlation between the amount of circulating fibrocytes and severity of COPD 71 , asthma 68 , and bronchiolitis obliterans syndrome (BOS) development in lung transplant patients 72 .…”